Kidney Disease

There are 958 kidney disease cases in my BVA dataset. The grant rate is 30.6%. But the headline number isn't the grant rate. It's the connection-type split. Of the 821 cases where I can identify how the veteran tried to connect the kidney disease to service, 401 of them went through secondary connection, almost half. And the secondary-connection grant rate (43.1%) runs roughly 11 points higher than the direct-connection grant rate (32.4%) and more than twice the presumptive-connection grant rate (18.4%).

That inversion is unusual. For most conditions, presumptive is the highest-yielding lane and secondary sits in the middle. For kidney disease, presumptive is the weakest path and secondary is the strongest. The reason is structural: most chronic kidney disease in veterans flows downstream from already-service-connected diabetes or hypertension, and the medical literature on that chain is well-established enough that the Board recognizes it. I want to walk through what 958 cases say about where these claims actually win, why direct connection is the harder path, where the Camp Lejeune presumption fits, and what the rating ladder under 38 CFR § 4.115a does to the math once service connection is established.

TL;DR

• Kidney disease grants at 30.6% across 958 BVA cases (293 granted, 320 denied, 345 remanded). The remand rate at 36.0% is unusually high. Nearly 9 points above the BVA overall average.
• Secondary connection is the dominant successful path. 401 cases (43.1% grant rate) versus 287 direct (32.4%) versus 125 presumptive (18.4%). The diabetes-to-kidney chain is doing most of the lifting.
• The strong-nexus grant rate is 97.0% across 99 cases. The weak-nexus grant rate is 0.0%. There are no weak-nexus grants in this subset. The cliff is absolute.
• 57.5% of C&P exams are flagged inadequate, above the 52.0% BVA average. Renal evaluation requires labs the basic exam often doesn't order.
• Camp Lejeune is a presumptive overlay that matters. 93 cases invoke it. The contaminated-water exposure window (1953 to 1987) and the listed conditions under 38 CFR § 3.307(a)(7) include kidney cancer.
• The rating ladder under DC 7530-7542 maps to renal function severity. 60% (36 cases) and 30% (34 cases) are the most common granted tiers. 100% (18 cases) generally requires dialysis or transplant.

958 Cases, 36% Remand Rate, and What That Tells You

The first thing the outcome split tells me is that kidney disease cases are unusually likely to get sent back rather than decided. The split:

• Granted: 293 cases (30.6%)
• Denied: 320 cases (33.4%)
• Remanded: 345 cases (36.0%)

The 36.0% remand rate is 8.7 points above the BVA overall remand rate of 27.3%. That's not a small difference. It's the Board telling regional offices and C&P examiners that the file isn't ready for adjudication often enough to be a structural pattern.

When I look at why these cases get remanded, the answer is usually some combination of inadequate renal function workup at the C&P exam, missing private nephrology records, or unresolved questions about the relationship between the kidney disease and a prior-service-connected condition. Kidney disease isn't a clinical exam diagnosis. It's a labs diagnosis. Estimated glomerular filtration rate (eGFR), serum creatinine, blood urea nitrogen, urinalysis findings, sometimes a biopsy: these are the markers the rating schedule cares about. A C&P examiner who didn't pull the recent labs is producing an exam that can't be used to assign a rating, and the Board sends those cases back.

The 57.5% inadequate-C&P rate in this dataset is consistent with that pattern. More than half of the C&P exams in kidney disease cases get flagged inadequate. That's above the 52.0% average across conditions, and the type of inadequacy is specific: missing labs, missing nephrology opinion, missing analysis of the secondary connection question. Those are all fixable problems on remand, which is why so many of these cases get a second chance rather than a denial.

For the veteran sitting at the Board with a remanded kidney disease claim, the remand isn't a loss. It's an instruction to develop the file. Get the recent labs. Get a nephrology opinion. Get the diabetes records pulled. The cases that come back from remand with that development in place often grant on the second pass.

Secondary Connection Is the Dominant Successful Path

Here's the finding that I think is the most important one in the whole dataset for kidney disease, and it's the one most veterans don't know about when they file.

The connection-type breakdown across the 821 cases where I can identify the theory:

• Direct service connection: 287 cases, 32.4% grant rate
• Secondary service connection: 401 cases, 43.1% grant rate
• Presumptive service connection: 125 cases, 18.4% grant rate
• Aggravation: 8 cases (sample too small to interpret)

Secondary is the largest bucket. It's also the highest-yielding bucket. Direct is second. Presumptive, which is the highest-yielding lane for almost every other condition I've looked at, is the worst-performing here.

Read that again. For most conditions, getting your claim into a presumptive lane is the structural advantage. For kidney disease, it's the structural disadvantage, and the secondary lane is where the wins live.

The reason isn't mysterious. Chronic kidney disease in adults is overwhelmingly driven by two conditions: diabetes mellitus and hypertension. Together they account for roughly 70% of all chronic kidney disease in the United States. Both of those underlying conditions are commonly service-connected for veterans: diabetes through the Agent Orange presumption for Vietnam veterans, hypertension through direct connection or the Agent Orange route (added 2022), and both through various other in-service exposure or onset pathways.

Once a veteran has service-connected diabetes or service-connected hypertension, the secondary claim under 38 CFR § 3.310 for kidney disease has a built-in medical foundation. The nephrology literature is unambiguous: long-standing diabetes causes diabetic nephropathy. Long-standing hypertension causes hypertensive nephrosclerosis. A nexus opinion that walks through that pathway (diabetes duration, glycemic control history, presence of microalbuminuria or proteinuria, progression of eGFR over time) is producing the kind of reasoning the Board treats as strong.

The 43.1% grant rate on the secondary path reflects that medical reality. The 32.4% grant rate on the direct path reflects how much harder it is to tie kidney disease to a specific in-service event or exposure when the medical literature points elsewhere.

Why Presumptive Is the Weakest Lane (and Where Camp Lejeune Fits)

The 18.4% presumptive grant rate is the outlier finding that needs unpacking, because at face value it contradicts the pattern across most other conditions.

The presumptive breakdown:

• Herbicide exposure: 179 cases
• Camp Lejeune: 93 cases
• Agent Orange (overlapping with herbicide): 42 cases
• Burn pit: 30 cases

The largest category, herbicide exposure for Vietnam-era veterans, runs into a specific structural problem. The Agent Orange presumptive list under 38 CFR § 3.309(e) includes Type 2 diabetes mellitus and certain cancers, but it does not include chronic kidney disease as a primary condition. Kidney cancer is listed (in the form of renal cell carcinoma in some presumptive determinations and various other formulations in others), but the broader category of chronic kidney disease, the bread-and-butter renal failure most veterans are dealing with, is not.

So when a Vietnam-era veteran files a kidney disease claim under the Agent Orange presumption, the Board is looking at a presumptive list that doesn't cover the diagnosis. The claim either fails on the presumption and gets reconsidered under direct connection (where it usually fails again), or the veteran refiles under secondary connection through service-connected diabetes (which is on the presumptive list) and the kidney disease becomes a downstream claim. That second pathway is where the grants live.

Camp Lejeune is the exception to the weak-presumptive pattern. Under 38 CFR § 3.307(a)(7), veterans who served at Camp Lejeune between August 1, 1953 and December 31, 1987 (a 34-year window) are presumed exposed to contaminated drinking water, and a list of conditions is presumptively service-connected. Kidney cancer is on the list. Several other conditions associated with the trichloroethylene, perchloroethylene, vinyl chloride, and benzene exposures are also on it.

For the 93 Camp Lejeune cases in my dataset, the presumptive pathway is more workable, especially when the diagnosis is kidney cancer specifically rather than generic chronic kidney disease. The exposure period is wide enough that any veteran with service at the base during the listed years qualifies for presumed exposure, and the documentation requirement is reduced to (a) qualifying service at Camp Lejeune in the qualifying period and (b) a current diagnosis on the listed condition list.

The smaller categories (burn pit and stand-alone herbicide cases not tied to the Agent Orange list) are running on weaker presumptive foundations. Burn-pit exposure isn't typically tied to kidney disease in the medical literature, and the PACT Act presumptive list under 38 USC § 1119 does not include chronic kidney disease as a presumptive condition. Some kidney cancers are listed, but the broader CKD population isn't.

The takeaway from the presumptive split: if you have a specific Camp Lejeune exposure history and kidney cancer specifically, the presumptive path under § 3.307(a)(7) is usable. If you have general CKD secondary to service-connected diabetes or hypertension, the secondary path under § 3.310 is the higher-yielding route. If you're trying to thread the needle on a stand-alone direct claim for CKD from in-service exposure without an underlying service-connected condition, you're on the hardest path in the data.

The Diabetes-to-Kidney Compensation Chain

I want to spend a section on the diabetes-to-kidney chain specifically, because it's the dominant winning pattern in the dataset and most of the veterans I see filing kidney claims don't frame it this way on the front end.

The chain works like this:

• Vietnam-era veteran with Southeast Asia service has Type 2 diabetes mellitus, presumptively service-connected under 38 CFR § 3.309(e) for Agent Orange exposure
• Diabetes is rated under 38 CFR § 4.119 DC 7913, typically at 20% or 40% depending on insulin requirements and complications
• Years of diabetes produce diabetic nephropathy, kidney damage caused by chronic hyperglycemia and the associated vascular changes
• The veteran files a secondary claim for chronic kidney disease under 38 CFR § 3.310, identifying the diabetes as the underlying service-connected disability
• A nephrology opinion documents the connection: duration of diabetes, presence of proteinuria or microalbuminuria, eGFR decline pattern, exclusion of other causes
• The kidney disease is rated under 38 CFR § 4.115a on the renal dysfunction scale

The same structure works with hypertension as the underlying disability. Hypertensive nephrosclerosis is the kidney damage caused by chronic uncontrolled hypertension, and it's similarly well-established in the medical literature. A hypertension-as-base, kidney-disease-as-secondary claim runs the same nexus analysis through the chronic vascular damage pathway.

The 401 secondary cases in my dataset are heavily concentrated in this pattern. The grant rate of 43.1% reflects how willing the Board is to accept the chain when the nephrology workup supports it. The cases that fail the secondary claim are usually cases where the underlying diabetes or hypertension hasn't been chronic enough to plausibly cause the renal damage, where the kidney disease has an alternative explanation the examiner identifies (polycystic kidney disease, glomerulonephritis from a different cause, medication nephrotoxicity), or where the eGFR doesn't actually show clinically significant impairment yet.

For veterans with service-connected diabetes who haven't filed for kidney disease, the question is whether the renal function workup shows nephropathy. If your most recent labs include eGFR in the 60-89 range with persistent albuminuria, or eGFR below 60, the chain is medically supportable. If your renal function is normal, the claim is premature. The threshold for filing isn't a specific number; it's whether a nephrology opinion can credibly tie current renal dysfunction back to the service-connected diabetes.

DC 7530-7542 in Plain English

Once kidney disease is service-connected, the rating mechanics under 38 CFR § 4.115a depend on which diagnostic code applies. The rating schedule for genitourinary conditions covers a range of renal pathologies, and the diagnostic code shapes the rating ladder.

The diagnostic-code framework

The framework (written from general knowledge of the rating schedule, not from this dataset) runs roughly like this:

• DC 7530: Chronic renal disease requiring regular dialysis. Rated at 100%.
• DC 7531: Kidney transplant. 100% for the first year following transplant. Reduces to a minimum 30% after the first year, with higher ratings if rejection or significant complications are present.
• DC 7532: Renal tubular disorders. Rated based on the underlying renal dysfunction criteria.
• DC 7533: Cystic diseases of the kidneys. Rated on renal dysfunction.
• DC 7541: Renal involvement in diabetes mellitus, sickle cell anemia, systemic lupus erythematosus, vasculitis, or other systemic disease. Rated on renal dysfunction.
• DC 7542: Neurogenic bladder. Rated as voiding dysfunction.

Code and rating-tier distribution in the BVA grants

The diagnostic code distribution in my dataset:

• DC 7530 (kidney transplant code grouping, dialysis-required cases): 69 cases
• DC 7541 (renal pathology, glomerular): 38 cases
• DC 7528 (urinary bladder/renal pelvis cancer): 17 cases
• DC 7500 (kidney removal): 8 cases

The underlying "renal dysfunction" ratings the schedule cross-references (the general framework) break out roughly as:

• 30%: Albumin constant or recurring with hyaline and granular casts or red blood cells, OR transient or slight edema, OR hypertension at least 10% disabling under DC 7101
• 60%: Constant albuminuria with some edema, OR definite decrease in kidney function, OR hypertension at least 40% disabling under DC 7101
• 80%: Persistent edema and albuminuria with BUN 40-80 mg% OR creatinine 4-8 mg% OR generalized poor health characterized by lethargy, weakness, anorexia, weight loss, or limitation of exertion
• 100%: Regular dialysis required, OR precluding more than sedentary activity from one of the following: persistent edema and albuminuria, BUN > 80 mg%, creatinine > 8 mg%, or markedly decreased function of kidney or other organ systems, especially cardiovascular

The granted rating distribution in my dataset:

• 30%: 34 cases
• 60%: 36 cases (the modal high tier)
• 80%: 13 cases
• 100%: 18 cases

The 60% and 30% tiers together account for the majority of granted cases where I can identify a tier. The 100% tier is reserved for veterans on dialysis, with end-stage renal disease, or with the kind of severe systemic dysfunction the schedule describes. Transplant cases drop from 100% to a minimum 30% after the first year, which is part of what produces the relatively high count at 30%.

For a single veteran in 2026, the dollar values matter:

• 30%: $537.42 per month
• 60%: $1,440.85 per month
• 80%: $2,059.75 per month
• 100%: $4,044.91 per month

The jump from 30% to 60% is roughly $903 per month, or about $10,840 per year tax-free. The jump from 60% to 100% is another $2,604 per month, or about $31,250 per year tax-free. These tier thresholds are driven by specific lab values and clinical findings, which means the right workup at the right time can move the rating substantially.

The Nexus Cliff Is Absolute Here

The nexus quality breakdown for kidney disease cases shows the sharpest version of the strong-versus-weak gap I've seen in any condition I've analyzed.

• Strong nexus: 99 cases, 97.0% grant rate
• Adequate nexus: 264 cases, 66.3% grant rate
• Weak nexus: 222 cases, 0.0% grant rate
• Missing nexus: 140 cases, 0.0% grant rate
• Not applicable: 233 cases, 9.4% grant rate

Two things stand out. The strong nexus grant rate at 97.0% is essentially a ceiling: when the medical opinion is well-reasoned and well-supported, the case almost always grants. And the weak-nexus and missing-nexus categories grant at zero. Not "low." Zero. There are no weak-nexus or missing-nexus kidney disease grants in my dataset.

That structural feature is unusual. Most conditions have a small number of weak-nexus grants: cases where the Board granted despite a poor nexus opinion for reasons specific to the file. For kidney disease, that doesn't happen. If the nexus opinion is weak or missing, the case denies.

The reason, I think, is that kidney disease cases are unusually dependent on the medical opinion. The condition itself isn't visible without lab work. The connection to service isn't visible without a specialist analysis. There's no observable injury, no contemporaneous documentation that the Board can fall back on. The case is the opinion. When the opinion is strong, the case grants. When the opinion is weak, the case denies.

What separates strong from weak in the BVA's coding:

• Strong nexus opinions are written by a nephrologist or an internist with relevant expertise, walk through the specific pathophysiology of the renal damage, identify the underlying service-connected condition (diabetes, hypertension, or similar) and document its duration and severity, address competing causes, cite the relevant medical literature, and arrive at an "at least as likely as not" or stronger conclusion with clear reasoning.
• Weak nexus opinions are written by a generalist provider without renal expertise, state conclusions without showing reasoning, fail to address the duration or severity of the underlying condition, ignore competing causes, or rely on generic statements about service.

The implication is that the nephrology opinion is the case. There's no other variable in the rating analysis that produces this kind of cliff. For a kidney disease claim that isn't running through the Camp Lejeune presumption, the strength of the private nephrology opinion is doing most of the lifting on the outcome.

What I Can't Tell You From This Data

There are real limits on what 958 BVA cases can teach you about your specific claim.

I can't tell you whether your kidney disease is medically caused by your service-connected diabetes or hypertension. That's a clinical question for a nephrologist with access to your records, not a question the aggregate data can resolve. The medical literature supports the chain in general; whether it applies to your specific eGFR trajectory, glycemic control history, and renal pathology findings is a case-by-case analysis.

I can't tell you whether your Camp Lejeune service during the qualifying window will trigger the presumption for your specific diagnosis. The presumptive list under 38 CFR § 3.307(a)(7) covers kidney cancer specifically, not the broader chronic kidney disease population. If your diagnosis is chronic glomerulonephritis or diabetic nephropathy, the Camp Lejeune presumption may not apply, and you may need to argue direct causation from the contaminated water exposure separately.

I can't tell you whether your specific lab values will support the 60% versus 30% versus 80% tier under the renal dysfunction schedule. The rating depends on the specific eGFR, creatinine, BUN, and clinical findings in your most recent workup. The thresholds in the regulation are specific, and your numbers either clear them or don't.

I can't tell you why the presumptive grant rate runs 18.4% in this dataset versus secondary at 43.1%. The most likely explanation is what I described above: that the most common presumptive lane (Agent Orange) doesn't actually cover the most common diagnosis (chronic kidney disease), so veterans filing under that theory often lose on the presumption and fall back to direct connection. But the data can't fully answer why the presumptive path performs so much worse than for other conditions.

What the data can tell you is the structural shape of these claims at the Board. Secondary outperforms direct outperforms presumptive. Strong nexus is a near-ceiling outcome and weak nexus is zero. The Camp Lejeune presumption matters for the specific subset it covers. The renal dysfunction rating tiers are driven by labs, not by symptoms.

What it can't tell you is which side of those distributions your case will land on.

What Wins a Kidney Disease Claim

Pulling the patterns together, the kidney disease claims that succeed at the Board usually have a few things in common.

A clear underlying service-connected condition. For most successful claims, the path runs through already-service-connected diabetes or hypertension. If you have service-connected diabetes and your most recent labs show eGFR decline or persistent albuminuria, the secondary claim is the dominant winning theory. The 401 secondary cases in my dataset, granting at 43.1%, are concentrated in this pattern.

A nephrology opinion that walks through the specific pathway. The opinion needs to identify the underlying condition, document its duration, show the renal damage progression over time, exclude competing causes, and arrive at an "at least as likely as not" conclusion with reasoning. The 97.0% grant rate on strong-nexus cases reflects how much the opinion matters. Generic primary care notes saying "kidney function is declining" don't move these cases. Specific nephrology analysis does.

Current labs that support the rating tier. Kidney disease rating is lab-driven. eGFR, creatinine, BUN, albumin or protein in urine, hypertension severity: these are the data points the rater uses to assign 30%, 60%, 80%, or 100%. If your most recent workup is more than a year old, the C&P examiner often won't have what's needed to assign the higher tier. Recent labs (within the last 90 days, ideally) are what allow the rating ladder to work in your favor.

Camp Lejeune documentation where applicable. For veterans who served at Camp Lejeune between 1953 and 1987 with a diagnosis on the presumptive list (kidney cancer specifically), the service evidence is the lever. The exposure is presumed once qualifying service is documented, so the case becomes a question of (a) proving the service and (b) proving the current diagnosis.

Resolved alternative explanations. Polycystic kidney disease, glomerulonephritis from autoimmune causes, medication-induced nephrotoxicity, and inherited renal conditions are the main alternative explanations C&P examiners point to in denied cases. The strong nexus opinion either rules these out or addresses them directly. A claim that doesn't engage with the alternative explanations is leaving an attack surface.

Patience through the remand cycle. The 36.0% remand rate in this dataset is high enough that most kidney disease claims at the Board are going to see at least one remand before the final decision. Treating the remand as a development opportunity rather than a loss (using the remand period to gather the labs, get the nephrology opinion, pull the diabetes records) is how the second-pass grants happen.

None of this is a guarantee. The 30.6% overall grant rate is the same 30.6% regardless of how clean your file is. But the structural levers that move kidney disease outcomes (secondary connection, strong nephrology opinion, current labs, Camp Lejeune presumption where applicable) are knowable, and the cases that grant tend to have them.

Bottom Line

Kidney disease is rated under 38 CFR § 4.115a using the renal dysfunction schedule, with diagnostic codes DC 7530-7542 covering the range of underlying pathologies. The Board grants kidney disease at 30.6% across 958 cases, with an unusually high 36.0% remand rate driven by inadequate C&P exams that fail to pull the labs and specialist opinions the schedule requires. Secondary service connection is the dominant successful path: 401 cases granting at 43.1%, compared to 287 direct cases granting at 32.4% and 125 presumptive cases granting at only 18.4%. The reason secondary outperforms presumptive is structural: the Agent Orange presumptive list under 38 CFR § 3.309(e) covers diabetes but not chronic kidney disease as a primary condition, so the highest-yielding path is to use service-connected diabetes (or hypertension) as the underlying condition and file kidney disease as secondary under 38 CFR § 3.310. Camp Lejeune is the meaningful exception on the presumptive side, with 93 cases invoking it for kidney cancer under 38 CFR § 3.307(a)(7) covering veterans who served at the base between 1953 and 1987. Nexus quality drives the outcome more sharply here than in most conditions: strong-nexus cases grant at 97.0% and weak-nexus and missing-nexus cases grant at 0.0%, an absolute cliff. The rating ladder once service connection is established runs 30%, 60%, 80%, and 100% based on specific lab values (eGFR, creatinine, BUN, proteinuria) and clinical findings. The 100% tier generally requires dialysis or transplant. For a single veteran in 2026, the difference between 30% and 100% is about $3,500 per month, tax-free, which makes the specific lab values driving the tier assignment the single most consequential evidentiary detail in the rating analysis.

Methodology and Limitations

• Data source: Statistics in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from 49,876 Board decisions, including 958 kidney disease cases. Outcomes within the kidney disease subset ran 30.6% granted, 33.4% denied, and 36.0% remanded. Rating criteria are paraphrased from 38 CFR § 4.115a (genitourinary). Secondary service connection mechanics are from 38 CFR § 3.310. Camp Lejeune presumption is at 38 CFR § 3.307(a)(7). Agent Orange presumption is at 38 CFR § 3.309(e). 2026 VA disability compensation figures are for a single veteran with no dependents.
• Sample size: 958 kidney disease cases overall. Within that subset, connection-type identification was possible in 821 cases: direct (287), secondary (401), presumptive (125), and aggravation (8). The presumptive subset breaks down into herbicide (179), Camp Lejeune (93), Agent Orange (42), and burn pit (30), with some overlap across categories. Diagnostic code distribution: DC 7530 (69), DC 7541 (38), DC 7528 (17), DC 7500 (8).
• Classification approach: Cases coded as kidney disease based on condition extraction from BVA decisions. Nexus quality (strong, adequate, weak, missing, not applicable) is assigned by Claim Raven's analysis pipeline based on the language and substance of medical opinions in each case. Connection type reflects the theory of service connection the Board addressed in its decision, which may not always match the original claim theory at the regional office.
• Limitations:
• The 18.4% presumptive grant rate is influenced by the structural mismatch between the Agent Orange presumptive list (which covers diabetes but not chronic kidney disease as a primary condition) and the most common renal diagnosis (chronic kidney disease). Cases that fail the presumption are sometimes recoded under direct or secondary theories, which shifts the distribution.
• The Camp Lejeune presumption covers kidney cancer specifically under § 3.307(a)(7). It does not cover the broader chronic kidney disease population. The 93 Camp Lejeune cases in my dataset include both presumptive grants on listed conditions and cases where the veteran argued Camp Lejeune exposure as a direct causation theory even when the diagnosis wasn't on the presumptive list.
• Rating tier distribution (30%, 60%, 80%, 100%) reflects the cases where the tier was specifically discussed in the BVA decision. Many BVA cases focus on service connection rather than rating tier, so the tier-distribution sample is smaller than the overall case count.
• The renal dysfunction rating schedule under § 4.115a is paraphrased here. The actual regulatory text includes specific lab thresholds and clinical findings that vary slightly across the diagnostic codes. The schedule is also subject to ongoing regulatory revision.
• The strong-nexus 97.0% grant rate reflects 99 cases, which is a meaningful but not enormous sample. The weak-nexus 0.0% grant rate reflects 222 cases, which is a more substantial sample.
• Cases that made it to the BVA are not representative of all kidney disease claims. Many kidney disease claims are granted at the regional office or never appealed, and they don't appear in this dataset.
• These observations reflect patterns from BVA decisions. They are not predictions of individual outcomes.